Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of RRG001 in Neovascular AMD
NCT06141460Phase 2Recruiting
- Sponsor
- Refreshgene Therapeutics
- Start
- Dec 2023
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of RRG001 in neovascular age-related macular degeneration (NVAMD) (4 arms), sponsored by Refreshgene Therapeutics. Primary endpoint: Safety and tolerability at Week 52. Started Dec 2023; status: recruiting.
02
Drugs
RRG001
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06141460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141460.